Objectives: The aim of this study is to compare the effect of platelet-rich fibrin (L-PRF) and bone morphogenetic protein-2 (rhBMP-2) in management of medication-related osteonecrosis of jaw (MRONJ).
Patients and Methods: Among 35 patients who were diagnosed with MRONJ, 12 patients were treated with L-PRF, 12 patients were treated with rhBMP-2 and 11 patients were treated with both L-PRF and rhBMP-2, evaluation of surgical sites was done for each patient postoperatively at 4 and 16 weeks.
Results: At 4 and 16 weeks postoperatively, MRONJ treated with both L-PRF and rhBMP-2 showed favorable outcomes with complete resolution of the lesions than that treated with L-PRF or rhBMP-2 alone. However this difference didn't reach the level of statistical significance (P=0.42).
Conclusion: The simultaneous use of both L-PRF and rhBMP-2 in management of MRONJ is a better treatment modality compared to the single use of each one of them alone.